Expansion of CD8+ Tem cells (GZMK+PD-1+) with novel TCRs in PBMCs after ICI treatment could contribute to a better clinical outcome in patients with NSCLC. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.